Algipharma

Executive Summary

AlgiPharma is a clinical-stage biopharmaceutical company pioneering alginate-based therapies for respiratory diseases, including cystic fibrosis (CF), COPD, and chronic infections. Founded in 2005 and headquartered in Bergen, Norway, the company leverages its proprietary alginate technology as both a drug delivery platform and a standalone active pharmaceutical ingredient (API). Its lead program targets the disruption of biofilms and mucus modulation, addressing high unmet needs in CF and COPD where current treatments offer limited efficacy. With in-house pharmaceutical-scale manufacturing capabilities and a robust patent portfolio, AlgiPharma is positioned to advance its pipeline through Phase 1 studies. The company's alginate oligomers have demonstrated potential in preclinical models to reduce mucus viscosity and enhance antibiotic efficacy against biofilm-associated infections. While still early-stage, the platform's versatility and strong IP protection provide a foundation for multiple therapeutic applications. Key risks include typical early-stage development hurdles, such as safety and efficacy validation in humans, as well as the need for additional funding to advance through Phase 2 trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for alginate oligomer in cystic fibrosis50% success
• Q4 2026Partnership or licensing deal for alginate drug delivery platform30% success
• Q2 2026Regulatory milestone for orphan drug designation in CF or COPD indication60% success